中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝硬化患者门静脉血栓形成的临床表现和危险因素

周仁华 李鹏 张艳婷 杨花 杨少奇

周仁华, 李鹏, 张艳婷, 杨花, 杨少奇. 肝硬化患者门静脉血栓形成的临床表现和危险因素[J]. 临床肝胆病杂志, 2016, 32(2): 275-278. DOI: 10.3969/j.issn.1001-5256.2016.02.015
引用本文: 周仁华, 李鹏, 张艳婷, 杨花, 杨少奇. 肝硬化患者门静脉血栓形成的临床表现和危险因素[J]. 临床肝胆病杂志, 2016, 32(2): 275-278. DOI: 10.3969/j.issn.1001-5256.2016.02.015
Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. J Clin Hepatol, 2016, 32(2): 275-278. DOI: 10.3969/j.issn.1001-5256.2016.02.015
Citation: Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. J Clin Hepatol, 2016, 32(2): 275-278. DOI: 10.3969/j.issn.1001-5256.2016.02.015

肝硬化患者门静脉血栓形成的临床表现和危险因素

DOI: 10.3969/j.issn.1001-5256.2016.02.015
详细信息
  • 中图分类号: R575.2

Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis

  • 摘要:

    目的研究肝硬化患者门静脉血栓(PVT)形成的临床表现及危险因素。方法收集2008年4月-2015年4月宁夏医科大学总医院收治的肝硬化患者资料541例。其中76例肝硬化合并PVT的患者为研究组,同阶段通过匹配患者的性别、年龄及肝功能Child-Pugh分级,76例肝硬化不合并PVT为对照组。对比分析两组患者的临床资料及相关检查指标。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验,并应用非条件Logistic回归模型筛选肝硬化PVT形成的独立危险因素。结果肝硬化PVT患者中,42.1%(32/76)隐匿起病,57.9%(44/76)有明显临床表现。大部分患者肝功能分级为Child-Pugh B和C级。血小板、血糖、中性粒细胞百分比、重度食管胃底静脉曲张、血浆D-二聚体、门静脉宽度、脾脏厚度在两组患者中差异有统计学意义(P值均<0.05)。进一步非条件Logistic回归模型分析显示中性粒细胞百分比[比值比(OR)=1.044,P=0.040]、血浆D-二聚体(OR=0.091,P<0.001)、门静脉宽度(OR=0.030,P=0.008)、脾脏厚度(OR=0.427...

     

  • [1]TSOCHATZIS EA,SENZOLO M,GERMANI G,et al.Systematic review:portal vein thrombosis in liver cirrhosis[J].Aliment Pharmacol Ther,2010,31(3):366-374.
    [2]Chinese Society of Infectious Diseases and Parasitology,Chinese Society of Hepatology,Chinese Medical Association.Viral hepatitis prevention and treatment of plan[J].Chin J Infect Dis,2001,19(1):56-62.(in Chinese)中华医学会传染病与寄生虫病学分会,中华医学会肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62.
    [3]Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association.Guidelines for diagnosis and treatment of alcoholic diseases[J].Chin J Hepatol,2006,14(3):164-166.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):164-166.
    [4] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association,Chinese Medical Association.Guidelines for prevention and treatment of alcoholic liver disease(revised version 2010)[J].J Clin Hepatol,2010,26(3):229-232.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南(2010年修订版)[J].临床肝胆病杂志,2010,26(3):229-232.
    [5]CHEN H,HE CY,HAN GH.Prevention and therapeutic progress in portal vein thrombosis in liver cirrhosis[J].Chin J Dig,2014,34(1):7-10.(in Chinese)陈辉,何创业,韩国宏.肝硬化门静脉血栓预防和治疗进展[J].中华消化杂志,2014,34(1):7-10.
    [6]SMALBERG JH,KRUIP MJ,JANSSEN HL,et al.Hypercoagulability and hypo brinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis:similarities and differences[J].Arterioscler Thromb Vasc Biol,2011,31(3):485-493.
    [7]SAUGEL B,LEE M,FEICHTINGER S,et al.Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.J Thromb Thrombolysis,2015,40(1):54-60.
    [8]ROMERO GóMEZ M,SUREZGARCIA E,LóPEZ LACOMBA D,et al.Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis[J].J Clin Gastroenterol,2000,31(3):237-240.
    [9]MANGIA A,VILLANI MR,CAPPUCCI G,et al.Causes of portal venous thrombosis in cirrhotic patients:the role of genetic and acquired factors[J].Eur J Gastroenrol Hepatol,2005,17(7):745-751.
    [10]KUMAR S,SARR MG,KAMATH PS.Mesenteric venous thrombosis[J].N Engl J Med,2001,345(23):1683-1688.
    [11]GARDINER C,PENNANEACH C,WALFORD C,et al.An evaluation of rapid D-dimer assays for the exclusion of deep vein thrombosis[J].Br J Haematol,2005,128(5):842-848.
    [12]ZOCCO MA,DI STASIO E,de CRISTOFARO R,et al.Thrombosis risk factors in patients with liver cirrhosis:correlation with MELD scoring system and portal vein thrombosis development[J].J Hepatol,2009,51(4):682-689.
    [13]ZHANG L,WANG L,YANG GM.Analysis of risk factors of portal vein thrombosis in liver cirrhosis[J].Chin J Dig,2014,34(2):100-104.(in Chinese)张莉,王龙,杨根妹.肝硬化门静脉血栓形成的相关危险因素分析[J].中华消化杂志,2014,34(2):100-104.
    [14]LEEBEEK FW,KLUFT C,KNOT EA,et al.A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis[J].Gastroenterology,1991,101(5):1382-1390.
    [15]AMITRAN L,GUARDASCIONE MA,BRACACCIO V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis[J].J Hepatol,2004,40(5):736-741.
    [16]TUDWAY D,SANGSTER C.Utrasound diagnosis of portal vein thrombosis:following splenentomy[J].Postgrad Med J,1986,62(734):1153.
    [17]MENG L,LIU YX,YAO WT.Relation between neutrophil with leuocyte and gastroesophageal varices bleeding in patients with hepatocirrhosis[J].Shandong Med J,2012,52(28):26-27.(in Chinese)孟磊,刘云霞,姚文暾.肝硬化患者中性粒细胞及白细胞与胃食管静脉曲张破裂出血的关系[J].山东医药,2012,52(28):26-27.
  • 加载中
计量
  • 文章访问数:  2072
  • HTML全文浏览量:  8
  • PDF下载量:  465
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-07-08
  • 出版日期:  2016-02-20
  • 刊出日期:  2016-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回